Tips Finding the injection site Point of maximal tenderness (POMT) just distal to lateral epicondyle
Suspected adverse drug reactions, including possible metformin-associated B12 deficiency, can be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
HCPCS codes G0553 and G0554 should only be billed when there is ongoing use of the DMHT device and should not be billed in cases where the patient discontinues use of the DMHT device
TB-family peptides investigated for cytoskeletal remodeling and angiogenesis in cardiac ischemia models
